[Burkitt lymphoma, a diagnostic emergency]

Area of Science:

• Oncology
• Hematology
• Genetics

Background:

• Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma.
• It is characterized by a chromosomal translocation activating the c-myc oncogene.
• Diagnosis and treatment initiation are urgent due to rapid progression.

Purpose of the Study:

• To highlight the diagnostic and therapeutic urgency of Burkitt lymphoma.
• To review the main clinical features and treatment strategies.
• To discuss the role of chemotherapy and rituximab in managing this aggressive malignancy.

Main Methods:

• Review of clinical presentation, including common localizations (digestive tract, CNS, bone marrow).
• Discussion of potential complications like tumor lysis syndrome.
• Analysis of treatment outcomes with dose-dense chemotherapy and rituximab adjunction.

Main Results:

• Dose-dense chemotherapy regimens have significantly improved cure rates, particularly in pediatric cases.
• High toxicity is associated with intensive chemotherapy protocols.
• Rituximab is under investigation for high-risk pediatric groups and is standard for adults.

Conclusions:

• Burkitt lymphoma necessitates prompt diagnosis and intensive care.
• Effective chemotherapy regimens offer high cure rates but require careful toxicity management.
• The integration of rituximab represents a significant advancement in adult treatment and is being explored in pediatric high-risk groups.